<DOC>
	<DOCNO>NCT02142751</DOCNO>
	<brief_summary>Enterobacterieaceae ( specially Escherichia coli ) show resistance due multidrug-resistant Escherichia coli , plasmid mediate AmpC quinolone resistance cause chromosomal mechanism spread worldwide last decade . This important many isolates also resistant first-line agent fluoroquinolones aminoglycosides , leave available option therapy , condition associate increase morbidity- mortality length hospital stay . While carbapenems consider drug choice multidrug-resistant Escherichia coli AmpC producer , recent data suggest certain alternative may suitable type infection . At present time , find therapeutic alternative carbapenems cephalosporin treatment invasive infection due multidrug-resistant Escherichia coli critical . Fosfomycin discover 40 year ago investigate accord present standard , thus use clinical practice except desperate situation . It one so-considered neglect antibiotic high potential interest future . With aim demonstrate clinical non-inferiority intravenous fosfomycin compare meropenem ceftriaxone treatment bacteraemic urinary tract infection cause multidrug-resistant Escherichia coli . The investigator propose `` real practise '' randomise , control , multicentre phase III clinical trial compare clinical microbiological efficacy safety intravenous fosfomycin ( 4 gramme every 6 hour ) meropenem ( 1 gramme every 8 hour ) ceftriaxone ( 1 gramme every 24 hour ) target therapy previously specify infection ; change oral therapy accord predefined option allow arm 5 day . Follow-up study plan 60 day .</brief_summary>
	<brief_title>Fosfomycin Versus Meropenem Ceftriaxone Bacteriemic Infections Caused Multidrug Resistance E.Coli</brief_title>
	<detailed_description>The FOREST study phase 3 , randomise , control , multicentric , open-label clinical trial prove noninferiority fosfomycin versus meropenem target treatment bacteraemic UTI due ESBL-EC , design real practice trial . It non-commercial , investigator-driven clinical study fund public competitive call Instituto de Salud Carlos III , Spanish Ministry Economy ( PI13/01282 ) . The study coordinate investigator Hospital Universitario Virgen Macarena Seville , Spain ; sponsorship perform Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla ( FISEVI ) , sponsor-scientific responsibility delegate CTU ( Clinical Trial Unit—Hospital Universitario Virgen del Rocío , Seville , Spain ) . All participate patient relative must give write informed consent study procedure occur , include withdrawal biological sample study . The hypothesis test intravenous fosfomycin inferior meropenem target treatment bacteraemic UTI cause ESBL-EC term efficacy . The primary objective study demonstrate intravenous fosfomycin inferior meropenem reach clinical microbiological cure 5-7 day completion treatment . Secondary objective include compare early clinical microbiological response , 30-day mortality , hospital stay , recurrence rate , safety impact intestinal colonisation MDR Gram-negative bacillus , evaluation rate resistance development fosfomycin blood level concentration fosfomycin .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>≥18 year old hospitalized patient Negative pregnancy test fertile woman Episode clinicallysignificant monomicrobial urinary BSI due multidrugresistant E.coli susceptible fosfomycin meropenem ceftriaxone Urinary sepsis multidrug resistant E. coli isolation blood culture , require least one clinical criterion one follow urinalysis criterion : Clinical criterion UTI symptom ( dysuriac , urgency , suprapubic pain pollakiuria ) Lumbar back pain Costvertebral angle tenderness Altered mental status people 70 year old Intermittent permanent indwell foley catheter ( withdrawal 24 hour previous ) even without urinary symptom urinalysis criterion Urine dipstick test positive either nitrites leukocyte esterase Positive urine culture Signed informed consent form ( ICF ) execute prior protocol screen assessment Polymicrobial bacteremia No drainage renal abscess obstructive uropathy unresolved Pregnant careen woman Haematogenous infection Other concomitant infection Renal transplantation recipient Polycystic kidney Hypersensitivity and/or intolerance meropenem fosfomycin ceftriaxone Palliative care life expectance &lt; 90 day Septic shock time randomization New York Heart Association ( NYHA ) functional Class IV , hepatic cirrhosis renal impairment receive dialysis Active empiric treatment &gt; 72 hour Late randomization &gt; 24 hour multidrug resistant.coli blood culture´s identification Participation clinical trial active treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Escherichia coli</keyword>
	<keyword>Extended-spectrum β-lactamases ( ESBLs )</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>Urinary tract infection</keyword>
	<keyword>Bloodstream infection</keyword>
	<keyword>Fosfomycin</keyword>
	<keyword>Meropenem</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>intestinal colonization</keyword>
	<keyword>Recurrence</keyword>
	<keyword>multidrug resistance E.coli</keyword>
	<keyword>Ceftriaxone</keyword>
</DOC>